[go: up one dir, main page]

AR083361A1 - Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon - Google Patents

Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon

Info

Publication number
AR083361A1
AR083361A1 ARP110103727A ARP110103727A AR083361A1 AR 083361 A1 AR083361 A1 AR 083361A1 AR P110103727 A ARP110103727 A AR P110103727A AR P110103727 A ARP110103727 A AR P110103727A AR 083361 A1 AR083361 A1 AR 083361A1
Authority
AR
Argentina
Prior art keywords
dosage form
almidon
dissolution
immune response
forming agent
Prior art date
Application number
ARP110103727A
Other languages
English (en)
Original Assignee
Scherer Technologies Inc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Inc R P filed Critical Scherer Technologies Inc R P
Publication of AR083361A1 publication Critical patent/AR083361A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una forma de dosificación de rápida disolución (FDDF) para la administración de una vacuna se prepara utilizando una fórmula que contiene almidón, opcionalmente, junto con al menos un agente formador de matriz adicional, preferentemente, una combinación de gelatina y manitol, en la cual la respuesta inmune es inducida al paciente que la necesita.Reivindicación 23: La forma de dosificación de una vacuna sólida oral de rápida disolución que comprende: (a) una cantidad inmunogénica de virus de influenza desactivado; y (b) al menos un agente formador de matriz potenciador de la respuesta inmune; en la cual dicho al menos agente formador de matriz potenciador de la respuesta inmune es un almidón.
ARP110103727A 2010-10-08 2011-10-11 Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon AR083361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39123810P 2010-10-08 2010-10-08

Publications (1)

Publication Number Publication Date
AR083361A1 true AR083361A1 (es) 2013-02-21

Family

ID=44908091

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103727A AR083361A1 (es) 2010-10-08 2011-10-11 Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon

Country Status (17)

Country Link
US (1) US9956169B2 (es)
EP (2) EP3095441B1 (es)
JP (2) JP6061859B2 (es)
KR (1) KR101751964B1 (es)
CN (2) CN108434089B (es)
AR (1) AR083361A1 (es)
AU (1) AU2011312107B2 (es)
BR (1) BR112013009255B1 (es)
CA (1) CA2813146C (es)
DK (2) DK2624815T3 (es)
ES (2) ES2602506T3 (es)
HU (1) HUE052853T2 (es)
MX (2) MX386380B (es)
PL (1) PL3095441T3 (es)
PT (1) PT3095441T (es)
RU (2) RU2639447C2 (es)
WO (1) WO2012048333A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2602506T3 (es) * 2010-10-08 2017-02-21 R.P. Scherer Technologies, Llc Forma de dosificación de disolución rápida de una vacuna oral usando almidón
US9668970B2 (en) * 2013-12-02 2017-06-06 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US10272038B2 (en) 2013-12-02 2019-04-30 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
TWI745278B (zh) * 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 發泡性降低之疫苗組合物
CN104530489B (zh) * 2015-02-05 2017-07-07 湖南尔康制药股份有限公司 一种速溶于水的淀粉成膜组合物
CN109224191A (zh) * 2018-07-23 2019-01-18 西安交通大学医学院第附属医院 一种用于静脉输液用的无菌输液港辅助植入装置
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
MY191879A (en) 2019-07-31 2022-07-18 Catalent Uk Swindon Zydis Ltd Density flow meter for pharmaceutical formulation dosing
CA3193124A1 (en) 2020-09-17 2022-03-24 Catalent U.K. Swindon Zydis Limited Use of surfactant with high molecular weight fish gelatin based dosage formulations to improve flow characteristics
US20230364013A1 (en) 2020-10-08 2023-11-16 Catalent U.K. Swindon Zydis Limited Stable oral dispersible formulation for epinephrine
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103639A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
WO2026024894A2 (en) 2024-07-24 2026-01-29 De Alba Jorge Sublingual formulations of a peptide derived from chaperonin 60.1 and related methods

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
CA2158040A1 (en) * 1993-03-11 1994-09-15 Jacqueline D. Duncan Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
WO1997013531A1 (en) * 1995-10-13 1997-04-17 Zynaxis, Inc. Solid, orally administrable viral vaccines and methods of preparation
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
EP1579851A3 (en) * 1997-08-29 2009-09-02 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of use thereof
GB9722682D0 (en) 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
GB9901819D0 (en) * 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
AU1591701A (en) * 1999-11-12 2001-06-06 Fibrogen, Inc. Recombinant gelatins
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
JP2006502972A (ja) * 2002-05-07 2006-01-26 フェリング ベスローテン フェンノートシャップ デスモプレシンの口腔内分散性医薬製剤
AU2003259827B2 (en) * 2002-08-12 2008-09-04 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
MXPA05005528A (es) 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US8012505B2 (en) * 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CA2523372A1 (en) * 2003-05-02 2004-11-11 Warner-Lambert Company Llc Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
EP1670509A4 (en) * 2003-09-03 2007-10-31 Dendritherapeutics Inc MULTIPLEX VACCINES
US7972621B2 (en) * 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
EP1933867A1 (en) 2005-10-04 2008-06-25 Alk-Abello A/S Solid vaccine formulation
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
US20110129438A1 (en) 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
EP2190472A2 (en) * 2007-08-20 2010-06-02 Fraunhofer USA, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
WO2009108775A2 (en) * 2008-02-28 2009-09-03 R.P. Scherer Technologies, Inc. Process to minimize polymorphism
WO2010002418A2 (en) * 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
US20120034253A1 (en) * 2008-09-25 2012-02-09 Fraunhofer Usa, Inc. Influenza Vaccines, Antigens, Compositions, and Methods
KR101074271B1 (ko) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
WO2011026080A1 (en) * 2009-08-31 2011-03-03 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain
CA2777218C (en) * 2009-10-30 2016-09-27 Ix Biopharma Pte Ltd Fast dissolving solid dosage form
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
AU2011276426B2 (en) * 2010-07-08 2015-05-21 Wm. Wrigley Jr. Company Confection with gelatin complex
ES2602506T3 (es) * 2010-10-08 2017-02-21 R.P. Scherer Technologies, Llc Forma de dosificación de disolución rápida de una vacuna oral usando almidón

Also Published As

Publication number Publication date
ES2602506T3 (es) 2017-02-21
JP6061859B2 (ja) 2017-01-18
US20120087944A1 (en) 2012-04-12
RU2017137357A (ru) 2019-04-25
ES2842290T3 (es) 2021-07-13
DK2624815T3 (en) 2016-11-07
MX347101B (es) 2017-04-12
JP2016199605A (ja) 2016-12-01
RU2013119946A (ru) 2014-11-20
EP2624815A1 (en) 2013-08-14
DK3095441T3 (da) 2021-01-11
PL3095441T3 (pl) 2021-06-14
RU2639447C2 (ru) 2017-12-21
US9956169B2 (en) 2018-05-01
HUE052853T2 (hu) 2021-05-28
JP2013539766A (ja) 2013-10-28
AU2011312107A1 (en) 2013-05-02
WO2012048333A1 (en) 2012-04-12
PT3095441T (pt) 2021-01-14
EP2624815B8 (en) 2016-09-21
KR101751964B1 (ko) 2017-06-28
EP3095441B1 (en) 2020-12-02
MX386380B (es) 2025-03-18
CN103347494A (zh) 2013-10-09
MX2013003875A (es) 2013-06-24
BR112013009255A2 (pt) 2016-07-26
RU2017137357A3 (es) 2019-04-25
JP6403738B2 (ja) 2018-10-10
KR20140091461A (ko) 2014-07-21
CA2813146C (en) 2018-12-18
CA2813146A1 (en) 2012-04-12
HK1253541A1 (zh) 2019-06-21
CN108434089B (zh) 2020-06-16
EP2624815B1 (en) 2016-08-10
EP3095441A1 (en) 2016-11-23
CN108434089A (zh) 2018-08-24
AU2011312107B2 (en) 2016-06-23
BR112013009255B1 (pt) 2021-02-23

Similar Documents

Publication Publication Date Title
AR083361A1 (es) Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
AR052625A1 (es) Nueva composicion
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
JP2009173664A5 (es)
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
CR10559A (es) Vacuna de influenza
JP2011518170A5 (es)
BR112015017451A2 (pt) formulações farmacêuticas resistentes à violação
PE20151588A1 (es) Vacuna contra el virus del dengue
UY32821A (es) Cápsulas de liberación sostenida
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
BR112015014243A8 (pt) composição de vacina para uso em populações imunocomprometidas e uso da mesma
CO6341567A2 (es) Vacuna contra el virus de papiloma humano
CO6761399A2 (es) Composiciones y métodos de vacuna del virus tipo 1b de diarrea viral bovina
CL2014003012A1 (es) Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c.
JP2012001565A5 (es)
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
ECSP10010567A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
BR112014023092A8 (pt) Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
BR112015010651A2 (pt) composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos
BRPI0811459A8 (pt) Preparação virossômica, uso de uma preparação virossômica, kit, e, métodos para vacinar um ser humano contra infecções de influenza, e para vacinar indivíduos mamíferos contra infecções da influenza

Legal Events

Date Code Title Description
FA Abandonment or withdrawal